secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116593
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Novavax's COVID-flu combo and standalone flu vaccines
--------------------------------------------------------------------------------

- FDA removed clinical hold on Novavax's IND for CIC and stand-alone influenza candidates on Nov 11.
- Hold was placed Oct 16 due to a serious adverse event (motor neuropathy, later ALS) in a Phase 2 participant.
- Novavax provided additional data confirming the event was not related to the vaccine.
- FDA cleared Novavax to begin enrollment in the planned Phase 3 trial for both vaccine candidates.
- Novavax will work with investigators to resume trial activities as quickly as possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924116593/0001104659-24-116593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924116593/tm2428029d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer